PCRX analyst estimates
Pacira BioSciences (PCRX) analyst ratings, the average price target and its range, and every firm's latest call.
PCRX analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 9, 2026 | Truist Financial | Pacira downgraded to Hold from Buy at Truist | $36.50 |
| Oct 9, 2026 | H.C. Wainwright | Pacira downgraded to Neutral from Buy at H.C. Wainwright | $36.50 |
| Oct 7, 2026 | Truist Financial | Pacira price target raised to $31 from $30 at Truist | $31.00 |
| Sep 23, 2026 | Oppenheimer | Pacira initiated with an Outperform at Oppenheimer | $32.00 |
| Sep 9, 2026 | Leerink Partners | Pacira initiated with a Market Perform at Leerink | $28.00 |
| Aug 17, 2026 | Truist Financial | Pacira reinstated with a Buy at Truist | $30.00 |
| Aug 5, 2026 | RBC Capital | Pacira price target raised to $25 from $24 at RBC Capital | $25.00 |
| May 1, 2026 | Needham | Pacira price target raised to $32 from $30 at Needham | $32.00 |
| Dec 8, 2025 | Barclays | Pacira initiated with an Equal Weight at Barclays | $27.00 |
| Feb 28, 2025 | H.C. Wainwright | Pacira price target raised to $48 from $39 at H.C. Wainwright | $48.00 |
| Feb 28, 2025 | Barclays | Pacira price target raised to $24 from $17 at Barclays | $24.00 |
| Jan 30, 2025 | Truist Financial | Truist Securities Upgrades Pacira Pharmaceuticals (PCRX) to Buy | $25.00 |
| Nov 7, 2024 | Piper Sandler | Pacira Pharmaceuticals (PCRX) PT Raised to $12 at Piper Sandler | $12.00 |
| Sep 24, 2024 | Jefferies | Pacira Pharmaceuticals (PCRX) PT Raised to $18 at Jefferies | $18.00 |
| Aug 13, 2024 | Truist Financial | Pacira downgraded to Sell from Buy at Truist | $8.00 |
- 9 firms rate PCRX: 1 buy, 8 hold, 0 sell.
- The average price target is $31.60 from 5 analysts, from $25.00 to $36.50.
Updated 2026-11-03 11:31 UTC